Parabilis Medicines, Inc. Common Stock (PBLS) Stock
Key stats
- Market cap
- $3.66B
- Price / Earnings ratio
- -19.8x
- EPS (TTM)
- -$92.40
- Volume
- Loading
- 52-week high
- $42.49
- 52-week low
- $22.66
Source: third-party data provider, as of November 13, 2026
Compare with PBLS
Recent news

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
PBLS

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
PBLS

Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
PBLS

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
PBLS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 52.07
- MACD 12/26/9
- -0.12
- EMA 9 of MACD
- -0.72
- MACD histogram
- 0.60
- SMA 50
- $31.36
- Price below SMA 50
- EMA 50
- $30.07
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
PBLS

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
PBLS

Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
PBLS

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
PBLS

Parabilis Medicines aims to raise $633 million in upsized US IPO
Parabilis Medicines aims to raise $633 million in upsized US IPO
PBLS

Parabilis Medicines aims to raise up to $475 million in US IPO
Parabilis Medicines aims to raise up to $475 million in US IPO
PBLS

Biopharmaceutical firm Parabilis Medicines files for US IPO
Biopharmaceutical firm Parabilis Medicines files for US IPO
PBLS
News tone: automated (AI) classification of the article's content, not a price prediction.
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. The company leverages its proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines. To the company's knowledge, its lead product candidate, zolucatetide, is the first-ever drug to directly target the interaction between β-catenin and the T-cell factor ("TCF") family of transcription factors.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Mathai Mammen M.D., Ph.D. | CEO, President, Treasurer & Chairman | 1967 |
| Mr. Thomas Rodolpho Kotarakos | Chief Financial Officer | 1982 |
| Ms. Teresa L. Jurgensen J.D. | Executive VP, Secretary & General Counsel | 1978 |
| Dr. Mohammed Fawzi Benzaghou M.D. | Chief Medical Officer | 1976 |
| Mr. John McGee Ph.D. | Scientific Co-Founder, Executive Vice President & Head of Platform | — |
| Dr. Rohin Mhatre Ph.D. | Chief Technical Operations Officer | 1965 |
| Ms. Kristen Stants | Chief People Officer | 1973 |
| Dr. Jonathan Hurov Ph.D. | Executive Vice President of Discovery Biology | — |
| Ms. Marie Nguyen M.D. | Senior VP & Head of Clinical Development | — |
| Dr. Markus Haeberlein MSc, Ph.D. | Executive Vice President of Discovery Science | 1969 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 52.07
- MACD 12/26/9
- -0.12
- EMA 9 of MACD
- -0.72
- MACD histogram
- 0.60
- SMA 50
- $31.36
- Price below SMA 50
- EMA 50
- $30.07
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $39.00
- Average
- $39.00
- High
- $39.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -13.4 | +22.4 | +14.9 | -18.2 | -7.0 | +8.8 |



